CAP: Major questions about the feasibility of this program arise amid CMS's decision to delay implementation

Why This Topic Matters

The delay affects how practices may obtain and bill for Part B drugs and signals potential changes to a Medicare payment program that stakeholders viewed as operationally challenging. Readers tracking Medicare reimbursement policy, vendor participation, and drug acquisition pathways will want to understand the implications.

Article Sections

1. CMS delay and program outlook

   Summarizes the reported delay in implementation and the revised timing CMS described for the program. It also notes the agency’s stated intent to improve the program before launch.

2. Vendor and practice concerns

   Covers reactions from prospective vendors and physician practices about participation, administrative burden, and feasibility. It includes stakeholder commentary on why the program was viewed skeptically.

3. Comments on risk, coverage, and pricing policy

   Describes issues raised in comments to CMS about vendor risk, shipment obligations, coverage verification, and payment policy concerns tied to drug pricing methodology. It also summarizes references to congressional intent and agency commentary.